Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. by O'Byrne, K. J. et al.
British Joumal of Cancer(1998) 77(11), 1950-1956
© 1998 Cancer Research Campaign
Cyclophosphamide, methotrexate and infusional
5-fluorouracil (infusional CMF) in metastatic breast
cancer
KJ O'Byrne, Ml Koukourakis, MP Saunders, AJ Salisbury, R Isaacs, S Varcoe, M Taylor, TS Ganesan, AL Harris
and DC Talbot
Imperial Cancer Research Fund Medical Oncology Unit, The Churchill, Oxford Radcliffe Hospital, Oxford OX3 7LJ, UK
Summary Bolus 5-fluorouracil (5-FU) is a phase-specific drug with a short plasma half-life that is used in combination with bolus
cyclophosphamide and methotrexate in the treatment of breast cancer. The efficacy of 5-FU can be improved by continuous intravenous
infusion using portable infusion pumps (infusional 5-FU). Infusional 5-FU, 200 mg m-2 day-1, in combination with standard doses of bolus
cyclophosphamide and methotrexate, was evaluated in a phase I/Il dose-finding study. The cyclophosphamide and methotrexate were
administered in 28-day cycles as follows: cohort 1, cyclophosphamide 600 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1; cohort
2, cyclophosphamide 400 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1; cohort 3, cyclophosphamide 480 mg m-2, days 1 and 8,
and methotrexate 40 mg m-2, day 1; cohort 4, cyclophosphamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, days 1 and 8.
Median overall survival was 10 months (range 3-21 months). Objective tumour responses were seen in 9 of 25 patients (36%, 95% Cl
18-58%), including 3 of 13 patients (23%) previously treated for metastatic disease. Cohorts 1 and 4 proved to be too toxic, with five of six
patients in cohort 1 and three of four in cohort 4 developing grade III/IV neutropenia. The dose intensity ofcyclophosphamide achieved was as
follows: cohort 1, 82%; cohort 2, 86%; cohort 3, 97%; cohort 4, 90%. Infusional 5-FU can be administered safely and is effective in combination
with cyclophosphamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day 1, in the treatment of metastatic breast cancer.
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5-Fluorouracil (5FU) was one ofthe earliest cytotoxic agents devel-
oped for the treatment of cancer and is a principal drug used in the
management ofbreast and colorectal carcinomas. Owing to a highly
variable bioavailability following oral administration, the intra-
venous route is considered to be the most efficacious (Christophidis
etal, 1978). Following intravenous bolus injection, 5-FU has a rapid
tissue distribution and very short plasma half-life, the drug being
undetectable 2 h after administration (Heggie et al, 1987). Between
60% and 90% of injected 5-FU or its metabolites can be recovered
from urine within 24 h of administration (McDermott et al, 1982).
Myelosuppression and mucositis are the main dose-limiting side-
effects of bolus administration. Larger cumulative doses are well
tolerated following continuous infusion as a consequence of the
altered plasma concentration profile (Spicer et al, 1988). This
schedule of administration results in less severe myelosuppression
but an increased incidence of palmar-plantar syndrome (Lokich et
al, 1981, 1983; Huan et al, 1989; Jabboury et al, 1989; Hansen,
1991). With the development of small portable infusion pumps it
has been possible to evaluate the activity and toxicity ofcontinuous,
ambulatory, intravenous administration of 5-FU alone or in combi-
nation with other drugs. Studies of single-agent infusional 5-FU at
Received 4 March 1997
Revised 24 November 1997
Accepted 25 November 1997
Correspondence to: DC Talbot
doses ofup to 300 mg m-2 day-' in advanced breast cancer show that
it is well tolerated with response rates of between 16% and 53%
(Hansen et al, 1987; Huan et al, 1989; Jabboury et al, 1989; Ng et al,
1994), including a response rate of 30% in patients with disease
refractory to conventional chemotherapy (Hansen, 1991). High
response rates have been reported when infusional 5-FU is
combined with bolus epirubicin and cisplatin (Smith et al, 1993,
1995; Jones et al, 1994).
The combination ofbolus cyclophosphamide, methotrexate and
5-fluorouracil (CMF) is the most frequently used chemotherapy
regimen in the management of breast cancer (Bonnadona and
Valagusa, 1985; Tannock et al, 1988; Engelsman et al, 1991;
Brandi et al, 1994). Continuous infusional 5-FU, rather than bolus
injections, may further improve the efficacy of this combination.
The dose intensity of cyclophosphamide is considered to be an
important factor in the activity of CMF (Henderson et al, 1988).
The 'classical' CMF regimen (28-day cycle) delivers a higherdose
intensity than the 21-day intravenous bolus schedule and a better
response rate has been reported (Engelsman et al, 1991).
One of the potential problems with using infusional 5-FU in
combination with cyclophosphamide and methotrexate is exacerba-
tion of myelotoxicity. The primary aim of the present study was to
evaluate the efficacy and tolerability ofa modified 'classical' CMF
regimen replacing bolus 5-FU with continuous infusional 5-FU,
given at 200 mg m-2 day-l, to lay the foundation for future random-
ized studies comparing infusional CMF with standard bolus treat-
ments in the management ofmetastatic breast cancer.
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Table 1 Schedules of infusional 5-fluorouracil, cyclophosphamide and methotrexate
Cyclophosphamide Methotrexate 5-Fluorouracil
Cohort 1 (six patients) 600 mg m-2, days 1 and 8 40 mg m-2, day 1 200 mg m-2, days 1 to 28
Cohort 2 (11 patients) 400 mg m-2, days 1 and 8 40 mg m-2, day 1 200 mg m-2, days 1 to 28
Cohort 3 (four patients) 480 mg m-2, days 1 and 8 40 mg m-2, day 1 200 mg m-2, days 1 to 28
Cohort 4 (four patients) 480 mg m-2, days 1 and 8 40 mg m-2, days 1 and 8 200 mg m-2, days 1 to 28
Table 2 Characteristics of each patient
Patient Age Performance Previous adjuvant Previous therapy for Evaluable
no. status chemotherapy metastatic disease disease
and/or hormones sites
Cohort 1, cyclophosphamide 600 mg m-2,
days 1 and 8, methotrexate 40 mg m-2, day 1
1
2
3
4
5
6
Cohort2, cyclophosphamide 400 mg m-2
days 1 and 8, methotrexate 40 mg m-2, day 1
1
2
3
4
60
58
60
41
50
1
0
0
1
1
Tam
Tam
CMF, Tam
CMF
Tam
2 57
42
33
52
69
5
6
7
8
9
10
11
Cohort 3, cyclophosphamide 480 mg m-2
days 1 and 8, methotrexate 40 mg m-2, day 1
1
2
3
51
62
60
48
62
39
48
48
40
51
4
Cohort 4, cyclophosphamide 480 mg m-2, days 1
and 8, methotrexate 40 mg m-2, days 1 and 8
1
2
3
4
36
57
68
42
57
CMF
Tam
Neo-CEF
1
0
0
0
0
2
0
1
1°
Tam
PMF
Tam
Tam
Neo-CEF, Tam
Tax, MMM, Provera
Epi, cAMP
Gem, Epi, Ag/Hc,
MPA
Tam, Tax
MMM, Epi
Epi, Tam
Tam, MPA,
BB94
Ag/Hc, CMF, Epi,
BB94
Epi+MPA, Bleo,
MPA
Epi/C, Gem, MMM,
Tam, Ag/Hc
Tam
0
0 CMF
Tam
Neo-CAF
CMF
Tam
0
1
1
0
Tam, Epi + Vin
Ag/Hc, Ex,
Dox-SL
Tam, Dox-SL
Tax
Tam
Previous treatments: Tam, tamoxifen; CMF, cyclophosphamide, methotrexate and 5-fluorouracil; PMF, prednimustine, methotrexate and 5-fluoracil; neo-CAF,
neoadjuvant cyclophosphamide, doxorubicin and 5-fluorouracil; neo-CEF, neoadjuvant cyclophosphamide, epirubicin and 5-fluorouracil; Epi, epirubicin; Vin,
vincristine; Dox-SL, liposomal doxorubicin; Tax, taxol; C, cyclophosphamide; Gem, gemcitabine; MMM, mitoxantrone, mitomycin C and methotrexate; Bleo,
bleomycin pleurodesis; Ag/Hc, aminoglutethimide and hydrocortisone; Ex, exemestane; BB94, batimastat; MPA, medroxyprogesterone acetate; cAMP, 8-chloro
cyclic adenosine monophosphate. Sites of disease, Br, breast; LN, lymph node; L, lung; H, liver; B, bone; S, skin; CW, chest wall; P, pleura; 0, other.
PATIENTS AND METHODS
Recruitment of patients
Patients over 18 years of age with WHO performance status < 2
and cytologically or histologically confirmed evaluable metastatic
breast cancer were considered eligible for the study. All patients
had a detailed pretreatment evaluation including physical examina-
tion, full blood count, biochemical profile and appropriate radio-
logical investigations for response assessment. Exclusion criteria
were: haemoglobin < 10 g dl-', white cell count < 3 x 109 1-',
neutrophil count < 1.5 x 109 1-1, platelet count < 100 x 109 1-', crea-
tinine > 180 ,umol 1-', bilirubin 2 34 gmol 1-', liver enzymes
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H, L, LN
L
H
H
CW, P, S
Br, CW, LN
L, S
LN
B, H, LN, P
CW, LN, S
B, H, P
LN, H, 0
B, H, L, LN
LN
B, H
L, S
B, LN
CW, H, L,
LN
LN, B
B
B, H, L, LN
B
B, 0, P
B, L, 0, P
L
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Table 3 Number of patients developing grade III/IV toxicities (WHO criteria)
in each cohort
Cohort 1 2 3 4
No. of patients 6 11 4 4
Leucopenia 6 3 0 2
Neutropenia 5 4 0 3
Anaemia 0 0 0 1
Thrombocytopenia 0 1 0 1
Neutropenic pyrexia 0 1 0 1
Fatigue 1 1 0 1
Mucositis 0 0 0 1
Nausea/vomiting 0 0 0 1
Table 4 Summary of dose modifications
Cohort 1 2 3 4
No. of patients 6 11 4 4
No. with dose reductions 3 4 0 2 (1)
No. with day 8 cancellation 2 (2) 0 0 1
No. with a week's cancellation 6 (3) 6 (3) 1 3 (4)
of 5-FU infusion
Numbers in parentheses indicate the number of patients who required dose
modification on more than one occasion.
[aspartate aminotransferase (AST), y-glutamyl transferase (yGT)
and alkaline phosphatase (ALP)] . three times the upper limit
of normal (unless caused by hepatic metastases), pregnancy or
concomitant serious clinical illness. Previous chemotherapy,
including adjuvant CMF chemotherapy or endocrine treatment,
was not an exclusion criterion.
As the agents employed were being used within their licensed
indication, the study was not submitted to the Research Ethics
Committee. However, all patients received an information sheet
detailing the nature of the treatment, the procedures involved and
the potential side-effects oftherapy and were only started on treat-
ment after giving their informed consent.
Treatment
The initial treatment schedule chosen was a modification of the
Iclassical' CMF regimen, with cyclophosphamide 600 mg m-2
being administered i.v. on days 1 and 8 ofa 28-day cycle rather than
cyclophosphamide 100 mg m-2 orally days 1-14. The infusional 5-
FU dose was based on that used in previous studies in breast cancer
either alone or in combination with epirubicin and cisplatin (Huan
et al, 1989; Smith et al, 1993; Jones et al, 1994; Ng et al, 1994). In
experimental models methotrexate has been shown to potentiate the
antitumour activity of 5-FU. As a result of this potentiation, the
side-effects of both agents may be increased. For this reason day 8
methotrexate was omitted in the initial schedule (Sotos et al, 1994).
The enrolment schedule to the modified 'classical' infusional CMF
regimen was based on standard criteria for a phase I study. We
planned to recruit between three and six patients to the initial cohort
based on the toxicities seen. If the initial schedule was well toler-
ated we planned to increase the dose intensity of methotrexate,
administering it on day 8 also. Cyclophosphamide is recognized to
be the main factor in CMF-induced toxicity (DeBrujn et al, 1991;
Shapiro et al, 1993). Therefore, in the case of significant toxicities
we intended to reduce the dose ofcyclophosphamide by 33% such
that the dose intensity ofcyclophosphamide would be equivalent to
that of standard 21-day bolus CME Subsequent dose adjustments
would be based on the experience gained with each treated cohort.
Before starting chemotherapy, a Hickman catheter was inserted
via the subclavian route and warfarin 1 mg p.o. daily commenced
as prophylaxis against thrombotic events (Bern et al, 1990;
Brown-Smith et al, 1990; Eastridge and Lefor, 1995). The treat-
ment was managed on an outpatient basis with infusional 5-FU at
a dose of 200 mg m-2 day-', administered as a continuous ambula-
tory infusion using a portable pump (Walkmed 350, Medfusion,
Duluth, GA, USA). The infusion bag contained 5-FU in a total
volume of 120 ml, at a concentration of 25 mg ml-' (3 g total).
Palmar-plantar erythrodysthesia, a potential complication of infu-
sional 5-fluorouracil therapy, was treated with pyridoxine 50 mg
t.i.d., p.o. (Fabian et al, 1990). The infusion was continued until
disease progression or 24 weeks oftreatment had been completed.
Three dose levels of cyclophosphamide were evaluated:
600 mg m-2, cohort 1; 400 mg m-2, cohort 2; and 480 mg m-2,
cohorts 3 and 4. Methotrexate 40 mg m-2was administered on day
1 in cohorts 1, 2 and 3, and on days 1 and 8 in cohort 4 (Table 1).
Dexamethasone 8 mg b.d. p.o./i.v. for 2 days and metoclopramide
10 mg q.d.s. p.o. for 3 days was started 12 h before the cyclophos-
phamide injection, as antiemetic prophylaxis.
Patients were assessed weekly with a full blood count and toxi-
city scored using standard WHO criteria. Renal, liver and bone
biochemical profiles were performed at the end of each treatment
cycle. The doses of cyclophosphamide and methotrexate were
reduced by 25% in patients experiencing grade III or IV haemato-
logical or non-haematological toxicity apart from alopecia or
nausea and vomiting, which could be controlled with standard
antiemetics. The 5-FU infusion was interrupted for 1 week when-
ever the neutrophil count fell to < 1.5 x 109 1-'. The subsequent
cycle was delayed only if the neutrophil count had not recovered
by the end of the cycle. Response evaluation according to WHO
criteria was performed after the second, fourth and sixth cycles of
treatment. Treatment was discontinued in patients with progressive
disease.
RESULTS
Patients' characteristics are summarized in Table 2. Twenty-five
women, median age 51 years (range 33-69 years) with stage IV
breast cancer, were recruited to the study. Six patients were
recruited to cohort 1. Because severe haematological toxicities
were seen in the initial cohort, and because of a number of side-
effects seen in cohort 2 (see below), we were cautious about
increasing the dose of cyclophosphamide to that used in cohorts 3
and 4. As a result, cohort 2 was expanded to include 11 patients.
Four patients were recruited to each ofcohorts 3 and 4.
Haematological toxicity
A total of 107 cycles of infusional CMF chemotherapy were
administered, all of which were evaluated for toxicity (Table 3).
The principal toxicity seen in cohort 1 was grade III/IV
leucopenia, which occurred in all six patients, five having grade
III/IV neutropenia. In the subsequent patient cohort, the
cyclophosphamide was reduced by 33% to 400 mg m-2, days 1 and
8. Of 11 patients recruited to cohort 2, grade III/IV neutropenia
developed in four, one of whom developed grade III/IV thrombo-
cytopenia. In cohorts 3 and 4 the cyclophosphamide dose was
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increased by 20% to 480 mg m-2 on days 1 and 8. Methotrexate
40 mg m-2 was given on day 1 in cohort 3. No significant side-
effects were seen. In cohort 4 methotrexate was administered on
days 1 and 8. Grade III/IV neutropenia developed in two patients
and was associated with pyrexia in one and grade III fatigue in the
other. The patient with the neutropenic pyrexia also developed
grade III anaemia, grade IV thrombocytopenia, grade IV mucositis
and grade III nausea and vomiting. As a result of these excessive
toxicities, the regimen was discontinued after a total of six cycles
of treatment had been administered to four patients. In subsequent
cycles the day-8 methotrexate was omitted and the four patients
were treated as in cohort 3. Although 3 patients developed grade
III/IV neutropenia on one occasion each, no sepsis or other signif-
icant side-effects were seen.
Non-haematological toxicities
Fatigue was experienced by 13 of the 25 (52%) patients recruited
to the study, with grade III/IV fatigue being experienced by one
patient in each of cohorts 1, 2 and 4. In two cases, the grade III/IV
fatigue was associated with grade IV neutropenia. Treatment was
stopped in one patient in cohort 2 with persistent grade II fatigue.
Nausea was well controlled by metoclopramide and dexametha-
sone. Grade II nausea was seen in two patients, one each from
cohorts 1 and 2. Grade III nausea occurred in only one patient in
cohort 4. Apart from the day 1 and 8 bolus injections, there was no
need forregular use ofantiemetics throughout treatment. Grade III
mucositis was observed in one patient in cohort 4. Grade II
alopecia developed in two patients in cohort 1. Grade II
palmar-plantar syndrome was seen in one patient (cohort 1) and
responded to pyridoxine 50 mg t.i.d. p.o.
In four of 25 patients (16%) Hickman line-related deep-vein
thrombosis (DVT) occurred despite the use of prophylactic low-
dose warfarin 1 mg p.o. daily. One of these patients developed
lower lobe collapse of the left lung associated with a pleural effu-
sion. Investigations, including bronchoscopy, cytological evalua-
tion of pleural fluid and computerized tomography (CT) of the
thorax and liver, showed no evidence of disease progression and
the patient was treated as having a pulmonary embolus. Two
patients developed leg DVTs, one in cohort 1 and one in cohort 2,
the latter being complicated by pulmonary embolism. All patients
received anticoagulants, initially with heparin and subsequently
with warfarin. Thrombolytic therapy was not employed and there
was no need to remove the Hickman line in any of these patients.
One patient in cohort 3 developed a pneumothorax as a complica-
tion of Hickman line insertion. Hickman line-related infections
occurred around the insertion site or along the tunnel in five
patients, one in each ofcohorts 1, 3 and 4 and two in cohort 2. All
Table 5 Response and survival data
Patient Treatment Reason off Best Months Duration Survival
no cycles study response to response of response in months
Cohort 1, cyclophosphamide 600 mg m-2,
days 1 and 8, methotrexate 40 mg m-2, day 1
1 4 SD SD - 6 10
2 3 SD + neutropenia SD - 15 20
3 5 Patient decision PR 2 6 10
4 4 PD PD - - 5
5 2 PD PD - - 12
6 2 PD PD - - 4
Cohort 2, cyclophosphamide 400 mg m-2,
days 1 and 8, methotrexate 40 mg m-2, day 1
1 2 PD PD - - 3
2 6 Complete PR 2 7 14
3 6 Complete PR 2 8 10
4 4 PD PD - - 5
5 6 SVC thrombosis SD - 6 9
6 2 Neutropenic sepsis PR 2 10 14
7 6 Complete PR 2 11 21
8 6 Complete SD - 9 21
9 5 Fatigue PR 4 8 17
10 5 PD SD - 4 9
11 2 Worsening PS SD - 7 9
Cohort 3, cyclophosphamide 480 mg m-2
days 1 and 8, methotrexate 40 mg m-2, day 1
1 2 PD PD - - 6
2 6 Complete SD - 19 28a
3 2 PD PD - - 8
4 6 Complete PR 2 8 16
Cohort 4, cyclophosphamide 480 mg m-2,
days 1 and 8, methotrexate 40 mg m-2, days 1 and 8
1 5 PD PD - - 14
2 3 Recurrent neutropenia SD - 6 16
3 6 Complete PR 4 10 16
4 6 Complete CR 2 7 7
All patients received 5-fluorouracil 200 mg m-2 day as a continuous ambulatory infusion. CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; PS, performance status; SVC, superior vena cava. aAlive.
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cases were managed with oral antibiotics apart from one patient
who was initially treated with parenteral antibiotics. In three of
these cases grade III/IV neutropenia occurred during the same
cycle, although not at the time the infection was documented.
Dose intensity
Dose reductions are shown in Table 4. Five patients in cohort 1, nine
in cohort 2, one in cohort 3 and two in cohort 4 required dose delays.
The mean delay of chemotherapy administration between cycles in
cohorts 1, 2, 3 and 4 was 2.1, 1.8, 0.1 and 0.4 days respectively. A
25% dose reduction in cyclophosphamide and methotrexate was
indicated in three of six (50%), four ofeleven (36%) and two of four
(50%) patients in cohorts 1, 2 and 4 respectively. In cohort 3 one
patient with bone marrow infiltration was given a 25% dose reduc-
tion in cyclophosphamide on day 8 of cycle 1 because of grade II
thrombocytopenia. The patient was subsequently treated with full-
dose therapy without complications. The actual vs planned
cyclophosphamide dose intensity (DI) for each patient group was as
follows: cohort 1, 35.4 mg m-' day-' (vs 42.8, 82% DI); cohort 2,
24.7 mg m-2day-' (vs 28.6, 86% DI); cohort 3, 33.9 mg m- day-' (vs
34.3, 97% DI); and cohort 4, 30.7 mg m-2day-' (vs 34.3, 90% DI).
Infusional 5-FU was discontinued temporarily for toxicities or inter-
current illness in 16 patients; six ofsix, six ofeleven, one offour and
three of four patients in cohorts 1, 2, 3 and 4 respectively, this
measurebeing necessary on more than one occasion in three patients
in cohort 1, three in cohort 2 and three in cohort 4. In two patients
the infusion was interrupted because of pump failure for 3 and 7
days respectively.
Response and survival
Of 25 patients entered into the study, 20 had bidimensionally
measurable disease, and 5 evaluable disease. Response rates and
duration of response are shown in Table 5. One patient achieved a
complete response and eight achieved a partial response, giving an
overall response rate of 36% (CI = 18-58%). Of those patients
responding to treatment, eight had bidimensional measurable
disease sites, with a complete response being seen in the lung in
one patient, and partial responses being seen in the liver in six
patients and lymph node disease in one patient. In the other patient
with an objective response, sclerosis of an evaluable lytic lesion
within the sternum was recorded. Responses were seen in all four
cohorts. The median duration of response, measured from the start
of treatment to the time of disease progression, was 8 months
(range 6-11 months). To establish stable disease, formal disease
assessment had to demonstrate no evidence ofdisease progression
on at least two occasions following baseline evaluation. By these
criteria eight patients had stable disease lasting 4-15 months,
median 6.5 months (Table 5). Three of nine patients who had
previously been treated with either adjuvant (3-weekly CMF, one
patient), or neo-adjuvant chemotherapy (cyclophosphamide,
epirubicin and 5-FU, one patient; cyclophosphamide, doxorubicin
and 5-FU, one patient) also responded (Tables 2 and 5).
Of 12 patients who had not previously received cytotoxic
chemotherapy for metastatic disease, six objective responses
(50%) were seen, including one patient with a complete response.
This group included two patients previously treated with neoadju-
vant cytotoxic chemotherapy, one of whom responded to infu-
sional CMF (Tables 2 and 5). Of 13 patients previously treated
with cytotoxic agents for metastatic disease, three patients (23%),
including two also previously treated with adjuvantlneoadjuvant
cytotoxic chemotherapy, responded to treatment (Tables I and 4).
The median survival for all 25 patients was 10 months (range
3-28 months) with one patient in cohort 3 still alive after 28
months at last follow-up.
DISCUSSION
The combination ofcyclophosphamide, methotrexate and 5-FU is a
commonly used regimen for the adjuvant treatment ofbreast cancer
and for the management of advanced disease when response rates
of 29-60% are reported (Tannock et al, 1988; Engelsman et al,
1991; Falkson et al, 1991; Smith and Powles, 1993; Brandi et al,
1994; Hayes et al, 1995). Other cytotoxic regimens used in the
treatment of metastatic or relapsed breast cancer include mito-
mycin-C-mitoxantrone-methotrexate (MMM), single-agent taxane
therapy and anthracycline-based regimens including cyclophos-
phamide, doxorubicin and 5-fluorouracil (CAF), and doxorubicin
or epirubicin and paclitaxel (Smith and Powles, 1993; Hayes et al,
1995; Capri et al, 1996; Luck et al, 1996). MMM has equivalent
response rates to CMF chemotherapy (Smith et al, 1993; Smith and
Powles, 1993). Response rates to CAF are consistently higher
(55-82%) than those of CMF and there may be a survival advan-
tage of CAF compared with CMF (Falkson et al, 1991; Pfeiffer et
al, 1992, Hayes et al, 1995). On the other hand, toxicity associated
with CAF chemotherapy, in particular haematological toxicity,
emesis and alopecia, is substantially higher (Greene et al, 1994;
Hayes et al, 1995). On the basis of available evidence of efficacy,
CMF continues to be widely used as first-line therapy for patients
with newly diagnosed metastatic breast cancer (Hayes et al, 1995).
The rationale for using infusional 5-FU administration is based
on the S-phase-specific nature of the drug and its short plasma
half-life. Bolus administration is followed by rapid tissue distribu-
tion and short elimination half-life (Heggie et al, 1987). As a
result, only a small proportion of tumour cells are exposed to
appropriate concentrations of 5-FU at the sensitive phase of the
cell cycle. Administration of infusional 5-FU would theoretically
increase the exposure of sensitive tumour cells to the drug. Initial
studies of protracted intravenous infusion of5-FU were performed
in the treatment of colorectal cancer. These demonstrated that
5-FU 300 mg m-2 could be administered by continuous infusion,
without interruption, for up to 60 days or up to 36 g cumulative
dose (Lockich et al, 1981). Subsequent work showed a higher
response rate with infusional than bolus injection (Lokich et al,
1983). Single-agent infusional 5-FU at doses of 200-300 mg m-2
daily has been reported to have activity in metastatic breast cancer
(Jabboury et al, 1989; Ng et al, 1994), with one study reporting a
response rate of 53% in heavily pretreated patients (Huan et al,
1989). In a review of six phase II infusional 5-FU studies in
metastatic breast cancer a mean response rate of29% was reported
(Hansen, 1991). Non-randomized studies on large operable breast
tumours treated with a combination of infusional 5-FU and bolus
epirubicin and cisplatin (ECF) show response rates of up to 98%
(Smith et al, 1993, 1995). Furthermore, an overall response rate of
84% has been reported for ECF in 43 patients with metastatic (29
patients) and locally advanced (14 patients) breast cancer
including a complete response rate of 24% in the metastatic
patients (Jones et al, 1994). Both the unique combination ofagents
together with the higher overall dose of5-FU administered in each
cycle compared with that normally given in bolus regimens may
have contributed to this encouraging anti-tumour activity.
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The present study set out to establish the best-tolerated dose of
cyclophosphamide and methotrexate, given in a modified 'classical'
schedule, that could be used concomitantly with continuous infu-
sional 5-FU at a dose of200 mg m-2 in the treatment ofmetastatic or
relapsed breast cancer. This study demonstrates that cyclophos-
phamide 480 mg m-2, days 1 and 8, and methotrexate 40 mg m-2, day
1, is well tolerated when combined with infusional 5-FU in the treat-
ment ofmetastatic breast cancer.
Fatigue/lethargy was the most frequently reported side-effect,
being seen in just over half the patients in our study. Fatigue was
severe (grade III) in three patients. One patient with persistent
grade II fatigue elected to discontinue her treatment for this reason.
Fatigue/lethargy is a well-recognized complication ofCMF and our
findings are in keeping with those reported for the classical CMF
chemotherapy regimen (Smith et al, 1993). The palmar-plantar
syndrome, a complication of 5-FU, is seen more frequently with
infusional treatment in which up to 26% of patients develop grade
III toxicity (Jones et al, 1994; Smith et al, 1995). We observed
grade II palmar-plantar syndrome in only one patient. Oral pyri-
doxine has been reported as an effective therapy when this condi-
tion occurs as a side-effect of 5-FU treatment (Fabian et al, 1990).
In keeping with this, our patient's symptoms resolved on pyri-
doxine 50 mg t.i.d. p.o. Patients tolerated the ambulatory pump
well as reported in previous studies (Ng et al, 1994).
DVT occurred in 24% of our patients. In four cases this devel-
oped in relation to the Hickman line, despite the use of prophyl-
actic warfarin from the day of its insertion. In a study of 322
indwelling venous devices, Eastridge et al (1995) observed a
10% thrombosis rate not related to coagulation profiles of the
patients. Infusional 5-FU resulted in superior vena caval throm-
bosis in 9% ofpatients in the Edinburgh study (Ng et al, 1994). It
is possible that cyclophosphamide exacerbates phlebitis induced
by continuous 5-FU infusion, leading to an increased risk of
thrombosis.
In a study evaluating a 21-day schedule of infusional CMF in
28 patients, cyclophosphamide 750 mg m-2 and methotrexate
50 mg m-2 were given as i.v. bolus injections on day I only. The
infusional 5-FU was administered as in the present study. Despite
the fact that 23 patients had received previous chemotherapy, the
overall response rate was 50%. This included two patients with a
complete response who had had anthracycline-containing regi-
mens for metastatic liver and extensive locally recurrent disease.
The 21-day regimen was well tolerated, grade III neutropenia
being observed in 12 patients, grade III mucositis in nine and
grade II palmar-plantar syndrome in four (Mackay et al, 1996).
These results are consistent with the findings of our study, in
which 36% response rate (CI = 18-58%) was seen. Although
precise details of the DI of cyclophosphamide achieved is not
given in their study, the planned DI, 35.7 mg m-2, is similar to that
of the planned regimen received by patients in cohorts 3 and 4 of
our study, 34.3 mg m-2.
This study demonstrates that cyclophosphamide 480 mg m-2,
day 1 and 8, and methotrexate 40 mg m-2, day 1, appear well
tolerated in combination with continuous infusional 5-FU,
200 mg m-2 day-'. Taken in conjunction with the results reported
by Mackay et al (1996), this study supports the contention that
infusional CMF chemotherapy may have a role to play in the
management of metastatic breast cancer. These findings have laid
the groundwork for a randomized trial comparing infusional CMF
with conventional CMF and other combination regimens in the
treatment of locally advanced and metastatic breast cancer.
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